Breast Cancer

PathVysion gene test gaining ground as standard diagnostic

Published in Cancer Weekly, June 17th, 2003

The National Comprehensive Cancer Network (NCCN) has updated its Practice Guidelines in Oncology to indicate that fluorescence in situ hybridization (FISH), the diagnostic technology used in Abbott's Vysis PathVysion test, may be more accurate than immunohistochemistry (IHC), the most commonly used test method for determining HER2 status in women with metastatic breast cancer.

The NCCN is a not for profit, tax-exempt corporation that is an alliance of the world's leading cancer centers. The organization's Clinical Practice Guidelines in Oncology are widely recognized and used as the standard for clinical policy in cancer care, and are the only comprehensive set of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-06-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry